Honeywell | May 27, 2022


Honeywell announced the signing of a non-binding memorandum of understanding (MoU) with Narayana Hrudayalaya Limited to identify, assess and collaborate on opportunities for the latter's digital transformation journey. This will enable Narayana Health to offer technology-driven, affordable and accessible healthcare for all. The MoU is subject to definitive agreements to be executed between Honeywell and Narayana Health.

"These are times of great promise and even greater opportunities in healthcare innovation. At Honeywell, we recognize this and have pivoted towards the development of technologies that will shape the future of healthcare delivery. The MoU with Narayana Health – one of India's foremost healthcare service providers – offers us an opportunity to create a strategic technology development roadmap that will eventually transform India's healthcare industry," said Suresh Venkatarayalu, Chief Technology Officer, Honeywell.

"Sensors and digital technology will disrupt health care delivery. Narayana Healthcare is delighted to work with Honeywell to develop digital technologies for making health care safer, more accessible, and more affordable," said Dr. Devi Prasad Shetty, Chairman and Executive Director, Narayana Healthcare.

Honeywell's Advanced Sensing Technologies (AST) healthcare business builds on the company's global leadership in sensors to offer devices and software for hospitals, clinics and elderly care facilities to improve communication, collaboration and coordination of clinical care.

"The pandemic made it abundantly clear that healthcare organizations need technology that can be seamlessly integrated into existing systems and processes to streamline error prone tasks, enhance patient experience, and improve organizational agility," said Robert Robinson, Vice President and General Manager, Advanced Sensing Technologies Healthcare, Honeywell.

Based on the terms of the MoU, Honeywell and Narayana Health will work towards co-innovation and introduction of new products, establish technology development centers, co-create joint capabilities in technology development and research, and undertake the development of fire safety codecs that ensure an end-to-end life safety system to make hospitals safer. As a technology partner, Honeywell will also help enhance and optimize Narayana Health's digital processes and offer training to its employees.

The healthcare industry is continuously evolving to keep up with increasing regulatory pressures, while maintaining an environment where patients and staff feel safe. COVID-19 highlighted the need for bringing efficiencies in healthcare delivery to enable fewer personnel to do more onsite. The growth in telemedicine also opened newer avenues for hospitals to manage patient care. Healthcare providers often struggle with developing the right approach to stay ahead of these changes.  

To help meet some of these challenges, last year Honeywell launched its Real-Time Health Monitoring System (RTHMS). This is a smart edge-to-cloud communication platform for remote and real-time patient monitoring that acts as a bridge between caregiver and patient. This offering integrates hardware and software to improve care delivery, enhance healthcare worker productivity, and enable process efficiency. By digitizing and automating critical tasks, RTHMS can reduce hospital administrative tasks by 35%.1 

"Narayana Healthcare has made remarkable progress in using technology to improve clinical outcomes and increase healthcare delivery efficiency. Honeywell's sensor-based applications will complement our efforts in real-time patient monitoring and fire safety, raising the bar for others to meet,"

Dr. Emmanuel Rupert, Managing Director and Group Chief Executive Officer, Narayana Hrudayalaya Limited

Honeywell has a robust portfolio of healthcare technologies – from a patient's first visit, to diagnosis, and returning home from care, Honeywell has the technologies to help healthcare providers increase productivity, efficiency, and shape the future of their organizations.   

About Honeywell

Honeywell  is a Fortune 100 technology company that delivers industry-specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit


The paradigm shift in the digital clinical trial enterprise is here from an increase in trial adoption to enterprise scale.


The paradigm shift in the digital clinical trial enterprise is here from an increase in trial adoption to enterprise scale.

Related News


CrowdHealth Secures $6M Series A for Community-Powered Alternative to Health Insurance

CrowdHealth | December 12, 2022

CrowdHealth recently secured $6 million in Series A funding from Next Coast Ventures and Activate Venture Partners. CrowdHealth plans to reinvest that funding back into the company—growing the CrowdHealth community and providing more tools for members that want to take charge of their healthcare and affordably break free from health insurance. Operating under a monthly membership model, CrowdHealth is a health care technology company that offers a new way to use and pay for health care services outside of health insurance. CrowdHealth harnesses the power of crowdfunding to help their members fund medical bills, keeping them out of medical debt without being exploited by health insurance companies. Instead of paying a high premium for insurance companies to decide what is or isn't covered, CrowdHealth members make a monthly membership payment and others in the Crowd help fund medical bills from their own accounts. In addition to the low monthly membership and the increased autonomy of crowdfunding, CrowdHealth also makes Care Advocates available to members. Care Advocates can coordinate with doctors and hospitals to negotiate lower costs for medical bills on behalf of members which is a far departure from the health insurance model that has existed for decades. "Our health insurance system is broken. Health insurance is cold, oftentimes unreliable, and perversely incentivized. We're changing the game at CrowdHealth. Treating people like real people, like extensions to our family, supporting them in their health journey, and helping get their bills paid at a low cost." Andy Schoonover, CEO of CrowdHealth CrowdHealth also offers a Bitcoin investment option for members who are interested in harnessing the power of Bitcoin. This new innovation, launched in October 2022 in partnership with Swan Bitcoin, will allow members to redirect a portion of their monthly subscription payment to a Swan account. About CrowdHealth CrowdHealth provides people with an opportunity to take control of their healthcare choices. Members are able to combat and overcome the challenges of traditional healthcare models effectively without the need for insurance.

Read More


Carbon Health Announces Best-in-Class Patient Outcomes from Diabetes Program

Carbon Health | December 01, 2022

In honor of National Diabetes Awareness Month in November, Carbon Health, a hybrid healthcare company that combines expert care with proprietary technology for easy everyday health, announces compelling new patient outcomes from its innovative diabetes program. To date, Carbon Health's diabetes program has helped two-thirds of its patients with uncontrolled diabetes achieve and maintain recommended glycemic targets, while patients with baseline A1c >9.0% in particular saw an impressive average A1c reduction of 4.2%. Carbon Health’s program is endocrinologist-led, integrated with primary care, and supported by a team of certified diabetes educators. It is also completely virtual, making it easily accessible to patients with no waiting or travel time involved. The Carbon Health electronic health record integrates data from continuous glucose monitors into the patient’s chart and enables seamless care coordination among all members of the care team. Patients are able to log meals and medications alongside their CGM data in the Carbon Health patient app, which is an everyday companion to their care. “Diabetes care traditionally involves fingerstick glucose monitoring and quarterly visits. We’re flipping that on its head with our measurement-based, personalized, and proactive diabetes program. We’re the only healthcare provider to integrate a combination of blood glucose data from a CGM device with food, physical activity, and medication into our electronic health record (EHR) to allow patients and their interdisciplinary care teams – including primary care providers – to have incredibly powerful insights at their fingertips. This continuous data better enables our care team to manage our patients virtually and offer proactive support when they need it the most, avoiding one-size-fits-all advice and broken handoffs.” Myoung Cha, Chief Strategy Officer at Carbon Health These new outcomes will be presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes and represent best-in-class results among a number of diabetes care solutions. A recent analysis of 204 patients in the program found that 66.8% with baseline A1c ≥7.0% are meeting the guideline-recommended 70% time in range in their latest four weeks of available CGM data. Meanwhile, 54.0% of this cohort reached 70% time in range in their first 4 weeks of participating in the program then maintained that target thereafter, indicating that glycemic control was achieved rapidly and effectively. Among patients with baseline A1c >9.0%, Carbon Health's diabetes program lowered A1c by an average of 4.2%, compared to 3.3% by a leading digital diabetes competitor. Additionally, Carbon Health has made the following enhancements to its diabetes program Meal rankings: This unique feature shows the connection between meals and blood sugar changes, helping patients to better understand on their own which meals they should favor or avoid/limit. Peer support: Diabetes care & education specialists facilitate peer support and open discussions through virtual group learning sessions. Educational content: Expanding the diabetes content library to increase patient knowledge includes offering an evidence-based comparison of popular diets and strategies for eating healthy on the road. Ongoing accountability: Carbon Health’s care team has developed bi-weekly notifications to support patients: celebrating when they reach their blood sugar goals and reaching out when they need help. The notifications also act as time-saving tools for providers, who can easily see changes and better drive care adherence. For those at higher risk of diabetes, including individuals with high blood pressure, high cholesterol and/or a family history of diabetes, Carbon Health also offers an improved metabolic health assessment in California. Due to the complete integration of CGM data with the Carbon Health app as well as meal rankings, the metabolic insights program now offers even more individualized and actionable insights so patients can see what works and make appropriate lifestyle shifts. Learn more and check eligibility for the metabolic insights program here. Diabetes and metabolic care at Carbon Health illustrate the company’s innovative care delivery model, Connective Care. Where typical primary care is anchored in a visit, Carbon Health combines technology and expert care so every patient can establish a relationship with their own integrated team, monitor and manage their health on the go, and access in-person care when and where they need it. “We’re proud of the outcomes that are driving real change for our patients. It’s truly only by leveraging this integrated primary care model that we are able to offer our patients care that is simple, flexible, and personal,” said Dr. Calvin Wu, Medical Director of the diabetes program and endocrinologist at Carbon Health. About Carbon Health Carbon Health is a modern healthcare company offering hybrid care for easier everyday health. By combining custom technology with expert care, Carbon Health enables patients to establish a direct relationship with an integrated team, monitor and manage their health on the go, and access in-person care when and where they need it. Building on the success of its nationwide urgent care network, Carbon Health treats the full spectrum of first-contact needs – from acute issues to chronic conditions, as well as ongoing physical and mental health needs. The company is also expanding into value-based care through work with employers, health plans, health systems, and other ecosystem partners.

Read More


Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Anumana | December 16, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” David McMullin, chief business officer of Anumana The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.” Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022. About Anumana Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More